A companion diagnostic is a medical device that corresponds to a drug. The companion diagnostic helps doctors determine if the corresponding drug is safe, effective, and ensure that the benefits outweigh the risks.
Chromosomal microarray analysis (CMA) is an established technology, which has demonstrated great sensitivity and specificity for detecting genome-wide copy number variants (CNVs). CMA represe...
Review of recent, post ACA, health care legislation for impact on physicians and clinical laboratories. Overview of possible new health care legislation and update on Medicare regulatory act...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
What is the future of personalized medicine? Featuring Dr. Trevor Hawkins (An Introduction to Companion Diagnostics), Dr. Patrick Joseph (Making It Personal for Patients), and Dr. Richard Fra...
The regulation of molecular testing continues to grow in complexity, in terms of the oversight by FDA, coverage determinations by Medicare contractors, and the payment amounts established by...
The development of CDx assays minimally requires a partnership between a pharmaceutical and a diagnostic company. It is not uncommon for the drug to be developed through an alliance of two ph...
As the scientific evidence base for pharmacogenetics continues to expand, the use of such information in clinical management and drug development will be in demand.
The FDA advises that the...
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...
The advent of massively parallel sequencing by next generation sequencing platforms now allow genomic approaches for individualizing healthcare. Genomic sequencing data reveals variants in ge...
Rheumatoid Arthritis (RA) is a heterogenous disease that affects 1.5% of the population. Similar to cancer, early detection coupled with an effective treatment strategy can significantly impr...
Development of a companion diagnostic can be critical to the success of a drug. Pharmaceutical companies are committing more and more of their efforts to discover and deliver targeted therapi...
Chromosomal microarray analysis (CMA) is an established technology, which has demonstrated great sensitivity and specificity for detecting genome-wide copy number variants (CNVs). CMA represe...
Review of recent, post ACA, health care legislation for impact on physicians and clinical laboratories. Overview of possible new health care legislation and update on Medicare regulatory act...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
What is the future of personalized medicine? Featuring Dr. Trevor Hawkins (An Introduction to Companion Diagnostics), Dr. Patrick Joseph (Making It Personal for Patients), and Dr. Richard Fra...
The regulation of molecular testing continues to grow in complexity, in terms of the oversight by FDA, coverage determinations by Medicare contractors, and the payment amounts established by...
The development of CDx assays minimally requires a partnership between a pharmaceutical and a diagnostic company. It is not uncommon for the drug to be developed through an alliance of two ph...
As the scientific evidence base for pharmacogenetics continues to expand, the use of such information in clinical management and drug development will be in demand.
The FDA advises that the...
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...
The advent of massively parallel sequencing by next generation sequencing platforms now allow genomic approaches for individualizing healthcare. Genomic sequencing data reveals variants in ge...
Rheumatoid Arthritis (RA) is a heterogenous disease that affects 1.5% of the population. Similar to cancer, early detection coupled with an effective treatment strategy can significantly impr...
Development of a companion diagnostic can be critical to the success of a drug. Pharmaceutical companies are committing more and more of their efforts to discover and deliver targeted therapi...